Cytori Therapeutics Inc (CYTX) Major Shareholder Sells $38,000.00 in Stock

Cytori Therapeutics Inc (NASDAQ:CYTX) major shareholder Bank Sa Swissquote sold 100,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $0.38, for a total transaction of $38,000.00. Following the completion of the sale, the insider now directly owns 5,496,655 shares of the company’s stock, valued at $2,088,728.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Bank Sa Swissquote also recently made the following trade(s):

  • On Thursday, January 11th, Bank Sa Swissquote sold 72,630 shares of Cytori Therapeutics stock. The stock was sold at an average price of $0.34, for a total transaction of $24,694.20.

Cytori Therapeutics Inc (NASDAQ:CYTX) remained flat at $$0.38 during midday trading on Friday. The company’s stock had a trading volume of 930,689 shares, compared to its average volume of 3,639,837. The firm has a market capitalization of $13.37, a P/E ratio of -0.42 and a beta of 3.21. Cytori Therapeutics Inc has a 12-month low of $0.22 and a 12-month high of $2.13.

Cytori Therapeutics (NASDAQ:CYTX) last posted its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.16) by $0.02. The business had revenue of $1.77 million during the quarter, compared to the consensus estimate of $2.04 million. Cytori Therapeutics had a negative net margin of 367.33% and a negative return on equity of 228.21%. During the same period in the prior year, the firm earned ($0.26) EPS. equities analysts expect that Cytori Therapeutics Inc will post -0.62 EPS for the current fiscal year.

Several research firms have commented on CYTX. B. Riley reissued a “hold” rating on shares of Cytori Therapeutics in a research report on Tuesday, November 7th. Zacks Investment Research downgraded shares of Cytori Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, November 9th. Finally, Maxim Group set a $5.00 price objective on shares of Cytori Therapeutics and gave the stock a “buy” rating in a report on Friday, January 5th.

An institutional investor recently raised its position in Cytori Therapeutics stock. Sabby Management LLC increased its position in shares of Cytori Therapeutics Inc (NASDAQ:CYTX) by 28.0% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,626,807 shares of the biotechnology company’s stock after buying an additional 355,504 shares during the period. Sabby Management LLC owned 4.69% of Cytori Therapeutics worth $1,789,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 7.41% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.com-unik.info/2018/01/12/cytori-therapeutics-inc-cytx-major-shareholder-sells-38000-00-in-stock.html.

About Cytori Therapeutics

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.

Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit